Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer.

Despite advances in its treatment, lung cancer still represents the most common and lethal tumor. Because of that, efforts to decipher the pathophysiological actors that may promote lung tumor generation/progression are being made, with the final aim of establishing new therapeutic options. Using a transgenic mouse model, we formerly demonstrated that the sole activation of the MEK5/ERK5 MAPK route had a pathophysiological role in the onset of lung adenocarcinomas.

MEK5 promotes lung adenocarcinoma.

http://ow.ly/M9e830mZb8N